Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$206.39 - $268.73 $9,700 - $12,630
-47 Reduced 4.93%
907 $187,000
Q1 2024

May 14, 2024

SELL
$203.52 - $273.43 $3,663 - $4,921
-18 Reduced 1.85%
954 $258,000
Q4 2023

Mar 26, 2024

SELL
$164.52 - $238.84 $73,046 - $106,044
-444 Reduced 31.36%
972 $229,000
Q2 2022

Aug 15, 2022

SELL
$204.13 - $302.4 $183,308 - $271,555
-898 Reduced 38.81%
1,416 $320,000
Q3 2021

Nov 15, 2021

BUY
$372.64 - $458.3 $32,419 - $39,872
87 Added 3.91%
2,314 $955,000
Q2 2021

Jul 29, 2021

BUY
$294.17 - $371.65 $19,709 - $24,900
67 Added 3.1%
2,227 $824,000
Q1 2021

Apr 12, 2021

SELL
$249.67 - $299.48 $38,948 - $46,718
-156 Reduced 6.74%
2,160 $662,000
Q4 2020

Feb 10, 2021

BUY
$222.0 - $252.62 $225,330 - $256,409
1,015 Added 78.02%
2,316 $644,000
Q3 2020

Nov 06, 2020

SELL
$175.56 - $226.45 $71,804 - $92,618
-409 Reduced 23.92%
1,301 $327,000
Q2 2020

Aug 13, 2020

SELL
$118.84 - $189.72 $30,185 - $48,188
-254 Reduced 12.93%
1,710 $300,000
Q1 2020

May 01, 2020

BUY
$98.9 - $178.34 $167,734 - $302,464
1,696 Added 632.84%
1,964 $268,000
Q1 2020

Apr 27, 2020

BUY
$98.9 - $178.34 $26,505 - $47,795
268 New
268 $1.96 Million
Q4 2019

Feb 13, 2020

SELL
$126.05 - $152.76 $111,806 - $135,498
-887 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$125.07 - $143.67 $13,007 - $14,941
104 Added 13.28%
887 $115,000
Q2 2019

Aug 15, 2019

BUY
$123.4 - $148.55 $96,622 - $116,314
783 New
783 $106,000
Q4 2017

Feb 15, 2018

SELL
$100.43 - $118.09 $809,064 - $951,333
-8,056 Closed
0 $0
Q3 2017

Nov 06, 2017

BUY
$96.72 - $109.26 $779,176 - $880,198
8,056
8,056 $944,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $7.83B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track High Point Advisor Group LLC Portfolio

Follow High Point Advisor Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.